BR112017010495A2 - tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionados - Google Patents
tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionadosInfo
- Publication number
- BR112017010495A2 BR112017010495A2 BR112017010495-4A BR112017010495A BR112017010495A2 BR 112017010495 A2 BR112017010495 A2 BR 112017010495A2 BR 112017010495 A BR112017010495 A BR 112017010495A BR 112017010495 A2 BR112017010495 A2 BR 112017010495A2
- Authority
- BR
- Brazil
- Prior art keywords
- poisoning
- inhibitor
- pharmaceutical compositions
- kits
- antidote
- Prior art date
Links
- 231100000572 poisoning Toxicity 0.000 title abstract 7
- 230000000607 poisoning effect Effects 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000729 antidote Substances 0.000 abstract 3
- 238000009098 adjuvant therapy Methods 0.000 abstract 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 abstract 2
- 239000002574 poison Substances 0.000 abstract 2
- 231100000614 poison Toxicity 0.000 abstract 2
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
?tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionados? por tratar-se a presente invenção de métodos de tratamento, composições farmacêuticas, sistemas e kits apropriados para terapia de primeira linha e/ou adjuvante com antídoto contra o veneno, por meio do uso de pelo menos um componente ativo, em alguns casos, de pelo menos dois componentes ativos e, em outros casos, não mais do que dois componentes ativos selecionados do grupo constituído de um inibidor seletivo de pla2 secretora (spla2 ou inibidor de pla2), um inibidor de metaloproteinase, um inibidor da serina protease, um antídoto contra o veneno, um ou mais inibidores da acetilcolinesterase ou um agonista do nachr acoplado a um antagonista de machr, um antagonista do receptor nmda e um inibidor do fator de espalhamento, para o tratamento de um indivíduo vítima de envenenamento, de preferência, no momento do envenenamento e muitas vezes dentro de um período de menos do que aproximadamente uma hora após o envenenamento ou 6 horas após o envenenamento e durante todo o curso do tratamento e, de vez em quando, com ou sem antídoto contra o veneno, como uma terapia adjuvante, após o envenenamento, por exemplo, causado por uma cobra ou por um invertebrado.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462082895P | 2014-11-21 | 2014-11-21 | |
US62/082,895 | 2014-11-21 | ||
US201562131441P | 2015-03-11 | 2015-03-11 | |
US62/131,441 | 2015-03-11 | ||
US201562243374P | 2015-10-19 | 2015-10-19 | |
US62/243,374 | 2015-10-19 | ||
PCT/US2015/061834 WO2016081826A2 (en) | 2014-11-21 | 2015-11-20 | Envenomation therapies and related pharmaceutical compositions, systems and kits |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017010495A2 true BR112017010495A2 (pt) | 2018-04-03 |
BR112017010495B1 BR112017010495B1 (pt) | 2023-12-05 |
Family
ID=56014685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010495-4A BR112017010495B1 (pt) | 2014-11-21 | 2015-11-20 | Composição farmacêutica |
Country Status (18)
Country | Link |
---|---|
US (2) | US11000506B2 (pt) |
EP (1) | EP3220902A4 (pt) |
JP (1) | JP6883515B2 (pt) |
KR (1) | KR20170086089A (pt) |
CN (1) | CN107249578B (pt) |
AU (1) | AU2015349774B2 (pt) |
BR (1) | BR112017010495B1 (pt) |
CA (1) | CA2968383C (pt) |
CR (1) | CR20170259A (pt) |
EA (1) | EA037262B1 (pt) |
IL (1) | IL252418B (pt) |
MA (1) | MA40998A (pt) |
MX (1) | MX2017006551A (pt) |
MY (1) | MY187053A (pt) |
PH (1) | PH12017500927A1 (pt) |
SG (1) | SG11201704106VA (pt) |
TW (1) | TWI745280B (pt) |
WO (1) | WO2016081826A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786483B2 (en) * | 2016-03-04 | 2020-09-29 | Hk Pharma | Tumescent contravenom drug delivery |
US20210220332A1 (en) | 2016-04-29 | 2021-07-22 | Ophirex, Inc. | Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury |
WO2018112313A1 (en) * | 2016-12-16 | 2018-06-21 | The Regents Of The University Of California | Neutralizing venomous biomacromolecules |
AU2018220515B2 (en) * | 2017-02-17 | 2022-06-30 | DayLife LLC | Universal antivenom |
CN108703975A (zh) * | 2018-08-30 | 2018-10-26 | 黄汝怡 | 一种治疗毒虫叮咬的涂抹剂 |
CN109260196A (zh) * | 2018-11-08 | 2019-01-25 | 中国科学院海洋研究所 | 巴马司他作为制备水母皮炎药物的应用 |
JP2023500791A (ja) * | 2019-10-15 | 2023-01-11 | オフィレックス インコーポレイテッド | 敗血症及び敗血症様症候群の早期管理及び防止 |
CN112494498A (zh) * | 2020-12-11 | 2021-03-16 | 中国人民解放军海军军医大学 | 四环素在制备预防或缓解水母蜇伤药物中的应用 |
WO2022216953A1 (en) * | 2021-04-08 | 2022-10-13 | Believe In A Cure, Inc. | Compounds for use in increasing foxg1 expression |
US20230054792A1 (en) * | 2021-05-14 | 2023-02-23 | Liverpool School Of Tropical Medicine | Methods and compositions for the treatment of snake bite |
CN113817738B (zh) * | 2021-10-20 | 2023-06-16 | 湖南科技学院 | 银杏长链非编码rna及其在银杏内酯生物合成中的应用 |
WO2023086343A1 (en) * | 2021-11-09 | 2023-05-19 | Ophirex, Inc. | Compositions and dosage forms for topical and transdermal delivery of actives and methods of use |
KR20230131139A (ko) | 2022-03-04 | 2023-09-12 | 한국원자력의학원 | 다라플라딥 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 방사선 조사에 의한 피부질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196193A (en) | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
MY112897A (en) | 1994-04-01 | 2001-10-31 | Lilly Co Eli | Ih-indole-3-glyoxylamide spla2 inhibitors |
AUPP076797A0 (en) * | 1997-12-05 | 1998-01-08 | Active (Pla) R&D Pty Ltd | Phospholipase inhibitor |
WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
PL219512B1 (pl) | 2003-04-14 | 2015-05-29 | Lohmann Therapie Syst Lts | Plaster miejscowy, zastosowanie plastra miejscowego i sposób wytwarzania plastra miejscowego |
WO2005027905A1 (en) | 2003-09-19 | 2005-03-31 | The Secretary Of State For Defence | Pharmaceutical compositions for the treatment of organophosphate poisoning |
EP1684753A2 (en) | 2003-10-28 | 2006-08-02 | Cornell Research Foundation, Inc. | Neuromuscular blocking agents and antagonists thereof |
WO2006088798A2 (en) | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
ES2413056T3 (es) | 2005-10-12 | 2013-07-15 | Advanced Accelerator Applications | Antagonista del péptido receptor Alfavbeta3 selectivo para aplicaciones terapéuticas y de diagnóstico |
US20090318534A1 (en) | 2006-09-27 | 2009-12-24 | The Regents Of The University Of California | Methods and compositions for the treatment of skin diseases and disorders |
US20090062369A1 (en) * | 2007-08-31 | 2009-03-05 | Joaquim Trias | Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels |
WO2009047762A1 (en) * | 2007-10-09 | 2009-04-16 | Yeda Research And Development Co. Ltd | Compositions and peptides for treatment of envenomation by pla2 containing venoms like bungarus multicinct venom |
WO2009093119A2 (en) | 2008-01-21 | 2009-07-30 | Med Discovery S.A. | Use of serine protease inhibitors in the treatment of skin diseases |
AU2010204986B2 (en) | 2009-01-14 | 2016-06-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
JP2013508305A (ja) | 2009-10-19 | 2013-03-07 | アミラ ファーマシューティカルズ,インク. | 関節内又は関節周囲の投与のための注射可能な製剤 |
US20130253060A1 (en) * | 2011-09-21 | 2013-09-26 | Harihara M. Mehendale | Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) |
US9795773B2 (en) | 2011-12-16 | 2017-10-24 | Indosys Limited | Medicament unit dose cartridge and delivery device |
AU2013312240A1 (en) * | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
US20140087003A1 (en) * | 2012-09-21 | 2014-03-27 | Ignacio Cisneros | Method for treating venomous bites and stings |
-
2015
- 2015-11-19 MA MA040998A patent/MA40998A/fr unknown
- 2015-11-20 JP JP2017527341A patent/JP6883515B2/ja active Active
- 2015-11-20 KR KR1020177016916A patent/KR20170086089A/ko not_active IP Right Cessation
- 2015-11-20 CR CR20170259A patent/CR20170259A/es unknown
- 2015-11-20 CA CA2968383A patent/CA2968383C/en active Active
- 2015-11-20 AU AU2015349774A patent/AU2015349774B2/en active Active
- 2015-11-20 CN CN201580074084.6A patent/CN107249578B/zh active Active
- 2015-11-20 US US15/528,418 patent/US11000506B2/en active Active
- 2015-11-20 EP EP15862088.0A patent/EP3220902A4/en active Pending
- 2015-11-20 TW TW104138525A patent/TWI745280B/zh active
- 2015-11-20 BR BR112017010495-4A patent/BR112017010495B1/pt active IP Right Grant
- 2015-11-20 WO PCT/US2015/061834 patent/WO2016081826A2/en active Application Filing
- 2015-11-20 EA EA201791122A patent/EA037262B1/ru unknown
- 2015-11-20 SG SG11201704106VA patent/SG11201704106VA/en unknown
- 2015-11-20 MX MX2017006551A patent/MX2017006551A/es unknown
- 2015-11-20 MY MYPI2017701802A patent/MY187053A/en unknown
-
2017
- 2017-05-19 PH PH12017500927A patent/PH12017500927A1/en unknown
- 2017-05-21 IL IL252418A patent/IL252418B/en active IP Right Grant
-
2021
- 2021-03-29 US US17/215,466 patent/US20210260029A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2017006551A (es) | 2018-01-15 |
WO2016081826A2 (en) | 2016-05-26 |
MY187053A (en) | 2021-08-27 |
PH12017500927A1 (en) | 2017-11-20 |
MA40998A (fr) | 2017-09-26 |
SG11201704106VA (en) | 2017-06-29 |
AU2015349774B2 (en) | 2020-07-02 |
KR20170086089A (ko) | 2017-07-25 |
US11000506B2 (en) | 2021-05-11 |
JP2017536372A (ja) | 2017-12-07 |
CN107249578B (zh) | 2021-01-26 |
JP6883515B2 (ja) | 2021-06-09 |
AU2015349774A1 (en) | 2017-06-01 |
BR112017010495B1 (pt) | 2023-12-05 |
US20170354642A1 (en) | 2017-12-14 |
CN107249578A (zh) | 2017-10-13 |
CA2968383C (en) | 2024-03-12 |
TW201632204A (zh) | 2016-09-16 |
EA201791122A1 (ru) | 2018-04-30 |
EP3220902A2 (en) | 2017-09-27 |
WO2016081826A3 (en) | 2016-07-14 |
IL252418A0 (en) | 2017-07-31 |
CR20170259A (es) | 2017-10-02 |
IL252418B (en) | 2021-01-31 |
US20210260029A1 (en) | 2021-08-26 |
CA2968383A1 (en) | 2016-05-26 |
EA037262B1 (ru) | 2021-03-01 |
EP3220902A4 (en) | 2018-11-07 |
TWI745280B (zh) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010495A2 (pt) | tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionados | |
CO2021005987A2 (es) | Compuestos de anillo fusionado | |
CL2021000387A1 (es) | Compuestos de anillo fusionado | |
ECSP23004573A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112017009648A2 (pt) | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. | |
UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
BR112017007460A2 (pt) | inibidores de di-hidropirrolopiridina de ror-gama | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
CO2020009670A2 (es) | Composiciones que comprenden microbiota coseleccionada y métodos para su uso | |
EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
BR112015023761A2 (pt) | moduladores de molécula pequena de pcsk9 e seus métodos e usos | |
BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
BR112016020135A8 (pt) | mistura de composto, seus usos, composição farmacêutica, e conjunto (kit) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/11/2015, OBSERVADAS AS CONDICOES LEGAIS |